Mineralys Therapeutics (MLYS)

• Market cap: $2.94B
• 1 day: -0.85%
• 5 days: -0.64%
• 1 month: -14.41%
• 3 months: -7.2%
• 6 months: 165.07%
• Year to date: 202.94%
• 1 year: 188.34%
• 5 years: 101.25%
• 10 years: 101.25%
• Sector: Healthcare
• Industry: Biotechnology

About: Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Employees: 51